Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Recent developments and current status of gene therapy using viral vectors in the United Kingdom.

Literature DB >> 15472267

Recent developments and current status of gene therapy using viral vectors in the United Kingdom.

Kate Relph¹, Kevin Harrington, Hardev Pandha.

Abstract

Mesh：

Year: 2004 PMID： 15472267 PMCID： PMC521577 DOI： 10.1136/bmj.329.7470.839

Source DB: PubMed Journal: BMJ ISSN： 0959-8138

× No keyword cloud information.

11 in total

1. Virus treatment questioned after gene therapy death.

Authors: S Lehrman
Journal: Nature Date: 1999-10-07 Impact factor: 49.962

Review 2. Latest development in viral vectors for gene therapy.

Authors: Kenneth Lundstrom
Journal: Trends Biotechnol Date: 2003-03 Impact factor: 19.536

Review 3. Progress and problems with the use of viral vectors for gene therapy.

Authors: Clare E Thomas; Anja Ehrhardt; Mark A Kay
Journal: Nat Rev Genet Date: 2003-05 Impact factor: 53.242

4. Looking into the safety of AAV vectors.

Authors: Mark A Kay; Hiroyuki Nakai
Journal: Nature Date: 2003-07-17 Impact factor: 49.962

5. The future of gene therapy.

Authors: Marina Cavazzana-Calvo; Adrian Thrasher; Fulvio Mavilio
Journal: Nature Date: 2004-02-26 Impact factor: 49.962

6. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.

Authors: M A Kay; C S Manno; M V Ragni; P J Larson; L B Couto; A McClelland; B Glader; A J Chew; S J Tai; R W Herzog; V Arruda; F Johnson; C Scallan; E Skarsgard; A W Flake; K A High
Journal: Nat Genet Date: 2000-03 Impact factor: 38.330

7. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease.

Authors: M Cavazzana-Calvo; S Hacein-Bey; G de Saint Basile; F Gross; E Yvon; P Nusbaum; F Selz; C Hue; S Certain; J L Casanova; P Bousso; F L Deist; A Fischer
Journal: Science Date: 2000-04-28 Impact factor: 47.728

8. Site-specific genomic integration produces therapeutic Factor IX levels in mice.

Authors: Eric C Olivares; Roger P Hollis; Thomas W Chalberg; Leonard Meuse; Mark A Kay; Michele P Calos
Journal: Nat Biotechnol Date: 2002-10-15 Impact factor: 54.908

9. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning.

Authors: Alessandro Aiuti; Shimon Slavin; Memet Aker; Francesca Ficara; Sara Deola; Alessandra Mortellaro; Shoshana Morecki; Grazia Andolfi; Antonella Tabucchi; Filippo Carlucci; Enrico Marinello; Federica Cattaneo; Sergio Vai; Paolo Servida; Roberto Miniero; Maria Grazia Roncarolo; Claudio Bordignon
Journal: Science Date: 2002-06-28 Impact factor: 47.728

Recent developments and current status of gene therapy using viral vectors in the United Kingdom.

1. Virus treatment questioned after gene therapy death.

Review 2. Latest development in viral vectors for gene therapy.

Review 3. Progress and problems with the use of viral vectors for gene therapy.

4. Looking into the safety of AAV vectors.

5. The future of gene therapy.

6. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.

7. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease.

8. Site-specific genomic integration produces therapeutic Factor IX levels in mice.

9. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning.

Review 10. ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus.

Review 1. [Molecular therapy in gastroenterology and hepatology].

2. Potential cellular and regenerative approaches for the treatment of Parkinson's disease.

3. Treatment of osteoarthritis using a helper-dependent adenoviral vector retargeted to chondrocytes.

4. Proteoglycan 4 expression protects against the development of osteoarthritis.